Institutional members access full text with Ovid®

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients

Hunt, Kelly K. MD; Yi, Min MS; Mittendorf, Elizabeth A. MD; Guerrero, Cynthia BA; Babiera, Gildy V. MD; Bedrosian, Isabelle MD; Hwang, Rosa F. MD; Kuerer, Henry M. MD, PhD; Ross, Merrick I. MD; Meric-Bernstam, Funda MD

doi: 10.1097/SLA.0b013e3181b8fd5e
Original Articles

Objective: Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer. This study was performed to evaluate the accuracy of SLN surgery for patients undergoing neoadjuvant chemotherapy versus patients undergoing surgery first.

Summary Background Data: Controversy exists regarding the timing of SLN surgery in patients planned for neoadjuvant chemotherapy. Proponents of SLN surgery after chemotherapy prefer a single surgical procedure with potential for fewer axillary dissections. Opponents cite early studies with low identification rates and high false-negative rates after chemotherapy.

Methods: A total of 3746 patients with clinically node negative T1-T3 breast cancer underwent SLN surgery from 1994 to 2007. Clinicopathologic data were reviewed and comparisons made between patients receiving neoadjuvant chemotherapy and those undergoing surgery first.

Results: Of the patients, 575 (15.3%) underwent SLN surgery after chemotherapy and 3171 (84.7%) underwent surgery first. Neoadjuvant patients were younger (51 vs. 57 years, P < 0.0001) and had more clinical T2-T3 tumors (87.3% vs. 18.8%, P < 0.0001) at diagnosis. SLN identification rates were 97.4% in the neoadjuvant group and 98.7% in the surgery first group (P = 0.017). False-negative rates were similar between groups (5/84 [5.9%] in neoadjuvant vs. 22/542 [4.1%] in the surgery first group, P = 0.39). Analyzed by presenting T stage, there were fewer positive SLNs in the neoadjuvant group (T1: 12.7% vs. 19.0%, P = 0.2; T2: 20.5% vs. 36.5%, P < 0.0001; T3: 30.4% vs. 51.4%, P = 0.04). Adjusting for clinical stage revealed no differences in local-regional recurrences, disease-free or overall survival between groups.

Conclusions: SLN surgery after chemotherapy is as accurate for axillary staging as SLN surgery prior to chemotherapy. SLN surgery after chemotherapy results in fewer positive SLNs and decreases unnecessary axillary dissections.

Significant controversy exists regarding the timing of sentinel lymph node surgery in patients planned for neoadjuvant chemotherapy. We examined the accuracy of the procedure and long-term outcomes of patients undergoing surgery first compared with after chemotherapy.

From the Department of Surgical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston, TX.

Reprints: Kelly K. Hunt, MD, Department of Surgical Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030. E-mail: khunt@mdanderson.org.

© 2009 Lippincott Williams & Wilkins, Inc.